Scarica l'app Stockscreener
1.42
5.19%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - Insider Monkey
Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks
PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria
PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News
EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors
PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com
Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com
Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PDSB Advances with Phase 3 Trial for Versamune HPV Therapy | PDS - GuruFocus
PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Trial and Announces Abstracts Selected for ASCO 2025 - Nasdaq
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update - TradingView
PDS Biotechnology (PDSB) Expected to Announce Earnings on Wednesday - Defense World
Pds Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
PDS Biotechnology Unveils Promising Flu Vaccine Data - TipRanks
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results - TradingView
Marshall Wace LLP Has $64,000 Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Renaissance Technologies LLC Acquires 76,800 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
THE CANADIAN INTERNATIONAL TRADE TRIBUNAL TERMINATES ITS PRELIMINARY INJURY INQUIRY IN RESPECT OF TIDEWATER RENEWABLES LTD.'S COUNTERVAILING (ANTI-SUBSIDY) AND ANTI-DUMPING DUTY COMPLAINT RELATING TO I - The Globe and Mail
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
PDS Biotechnology Enters $20M Securities Purchase Agreement - TipRanks
B. Riley Adjusts Price Target on PDS Biotechnology to $5 From $7, Maintains Buy Rating - marketscreener.com
B. Riley Expects Stronger Earnings for PDS Biotechnology - Defense World
PDS Biotechnology Director Sir Richard Sykes Retires - TipRanks
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces Three Abstracts Accepted for ASCO 2025 on Versamune® HPV Immunotherapy - Nasdaq
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
Raymond James Financial Inc. Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research - MarketScreener
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Globe and Mail
Blair William & Co. IL Purchases 35,757 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
3 Reasons to Avoid GAP and 1 Stock to Buy Instead - The Globe and Mail
PDSB stock touches 52-week low at $1.12 amid market challenges - Investing.com
Virtu Financial LLC Takes $89,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish - Asianet Newsable
HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price - Defense World
H.C. Wainwright cuts PDS Biotechnology stock target to $13 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts PDS Biotechnology stock target to $13 - Investing.com India
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
PDS Biotechnology Advances Cancer Immunotherapy Trials - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy - Investing.com
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):